Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Acquires 35,714,284 Shares of Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) major shareholder Group Gp Lp Column III acquired 35,714,284 shares of Tenaya Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average cost of $0.70 per share, with a total value of $24,999,998.80. Following the completion of the purchase, the insider now owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This represents a 262.62 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Tenaya Therapeutics Stock Performance

Shares of TNYA opened at $0.46 on Friday. The stock has a fifty day moving average price of $1.17 and a two-hundred day moving average price of $1.92. Tenaya Therapeutics, Inc. has a 52-week low of $0.39 and a 52-week high of $6.78. The company has a market cap of $36.05 million, a price-to-earnings ratio of -0.32 and a beta of 2.83.

Hedge Funds Weigh In On Tenaya Therapeutics

Several institutional investors have recently bought and sold shares of TNYA. JPMorgan Chase & Co. raised its position in Tenaya Therapeutics by 20,670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company’s stock valued at $7,373,000 after purchasing an additional 5,130,774 shares during the last quarter. Trustees of Columbia University in the City of New York bought a new position in Tenaya Therapeutics in the 4th quarter valued at $417,000. Jacobs Levy Equity Management Inc. raised its position in Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after purchasing an additional 226,466 shares during the last quarter. Virtu Financial LLC bought a new position in Tenaya Therapeutics in the 4th quarter valued at $150,000. Finally, Deutsche Bank AG raised its position in Tenaya Therapeutics by 304.1% in the 4th quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock valued at $185,000 after purchasing an additional 97,318 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on TNYA shares. Chardan Capital reissued a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Monday, February 3rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tenaya Therapeutics presently has an average rating of “Buy” and an average target price of $17.33.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.